Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

Inclusion Criteria:

• Participant must be a boy or girl, aged from birth (0 months) to less than (<) 18years at screening. Participants in Cohort 4 who are <6 months of age at screening,gestational age at birth had to be greater than or equal to (>=) 37 weeks

• Participant must weigh >3 kilogram (kg) at baseline and be within the 5th and 95thpercentiles (inclusive) for the participant's age, based on the World HealthOrganization (WHO) child growth standards; Body Mass Index (BMI) for age. In Cohorts 3 and 4, weight for height/length may be used instead of BMI for age according tothe local standard of care. Per WHO guidance, for Cohort 4, length will be used tocalculate the BMI instead of height

• For Cohorts 1 and 2 only: Heterosexually active girls may participate if they are ofnon-childbearing potential, or if they are using effective birth control methods andare willing to continue practicing birth control methods throughout MultidrugResistant Tuberculosis (MDR-TB) treatment and for 6 months after stopping TMC207treatment, or if they are non-heterosexually active or willing to practice sexualabstinence throughout MDR-TB treatment

• For Cohorts 1 and 2 only: Boys who engage in sexual activity that could lead topregnancy of the female partner must use at minimum a male condom throughout MDR-TBtreatment and for 3 months after stopping TMC207 treatment

• Participant must have confirmed or probable (clinically diagnosed or presumed)pulmonary and/or non-severe extrapulmonary MDR-TB, including pre-extensivelydrug-resistant TB (pre- extensively drug resistant [XDR]-TB) or XDR-TB infection,based on the case definitions of pediatric pulmonary and non-severe extrapulmonaryTB as described in the International (WHO) guidelines and in accordance with thelocal standard of care

• Participants must be starting the initial MDR-TB treatment at baseline or havestarted an MDR-TB treatment within 12 weeks of baseline and are willing to modify itif necessary to an acceptable MDR-TB regimen for use with TMC207

• Participant must be willing to permanently discontinue RMP from at least 7 daysbefore the baseline visit

• Participant must consent/assent to human Immunodeficiency virus (HIV) testing. Ifthe potential participant is a child aged <2 years, or if the participant is beingbreastfed or was breastfed within the last 8 weeks before screening, the mother mustalso consent to HIV testing unless an HIV test was performed within 1 month prior toscreening and documentation of HIV status can be provided. When documentedHIV-positive status is available prior to screening for participants in Cohort 4,HIV testing is not required

Exclusion Criteria:

• Participant has a clinically significant active medical condition or the presence ofany concomitant severe illness or rapidly deteriorating health condition, includingimmune deficiency (except HIV infection), which in the opinion of the investigatorwould prevent appropriate participation in the study, or that would makeimplementation of the protocol or interpretation of the study results difficult, orotherwise make the subject a poor candidate for a clinical study

• Participant is a girl who is pregnant, or breast-feeding, or planning to becomepregnant while enrolled in this study or within 6 months after stopping TMC207treatment

• Participant has known or presumed forms of extrapulmonary TB, other than:Lymphadenopathy (peripheral nodes or isolated mediastinal mass without significantairway compression); Pleural effusion or pleural fibrotic lesions

• Participant has a significant cardiac arrhythmia that requires medication or ahistory of risk factors for Torsade de Pointes, example heart failure, hypokalemia,known personal or family history of Long QT Syndrome, and untreated hypothyroidism